Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

A proliferative disease, cancer technology, applied in the fields of application, animal repellent, plant growth regulator, etc., can solve the problems of increased cost, increased risk of infusion complications, and prolonged hospital stay

Inactive Publication Date: 2010-02-24
CELATOR PHARMA INC
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This long infusion administration results in increased complexity, length of hospital stay, and increased cost and risk of infusion complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
  • Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
  • Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] In Vivo Trials Using CPX-351

[0045] CPX-351 (cytarabine:daunorubicin) liposomal injection has been studied in rats and dogs by single and repeated dose administration (3 doses given every other day, repeated after 2 weeks) of toxicology.

[0046] Single dose study. In the single dose study (Table 1), CPX-351 was administered by intravenous infusion over one hour and the animals were observed for 14 days. "Vehicle control" included liposomes containing copper gluconate but no drug. No drug-related deaths occurred in rats receiving a single dose of CPX-351. Dose-related changes in various hematological parameters and extramedullary hematopoiesis in the spleen and liver were observed in both males and females in the medium and high dose groups compared to control rats. The no observed adverse effect level (NOAEL) single dose of CPX-351 in rats was 10 mg / kg cytarabine: 4.4 mg / kg daunorubicin. In dogs given a single dose of CPX-351, high-dose (6 mg / kg cytarabine: 2...

Embodiment 2

[0055] Phase I clinical trial

[0056] Physical, chemical and drug information. CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs were present in liposomes in a 5:1 molar ratio that showed non-antagonistic activity in preclinical studies. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a molar ratio of 7:2:1. These liposomes have a nominal diameter of approximately 100 nm and are suspended in sucrose-phosphate buffer at pH 7.4. Sterilization was achieved by filtration through a 0.22 μm filter.

[0057] CPX-351 is supplied as a sterile, pyrogen-free, purple opaque 5 mL suspension in single-use 10 mL vials and is also available as a 20 or 25 mL suspension in 50 mL vials. CPX-351 was stored frozen (-20°C) and thawed at room temperature 60 minutes prior to dilution and administration. CPX-351 can also be stored lyophilized and...

Embodiment 3

[0127] Phase I Clinical Trial of CPX-351 - Case Study

[0128] Below are 5 case studies of patients treated in the ongoing Phase I clinical trial of CPX-351.

[0129] case study 1 - Response to CPX-351 in AML patients (even if not responding to prior conventional 7 / 3 cytarabine / daunorubicin therapy): Patient 02-011 is a 62-year-old male diagnosed with AML in 2007 from Received initial Revlimid treatment from September to November 2007 and showed no non-response. In December 2007, the patient was given standard conventional 7+3 cytarabine / daunorubicin therapy and remained unresponsive. Analysis of his bone marrow 14 days after initiation of conventional 7+3 cytarabine / daunorubicin treatment revealed 5% cellularity and 24% blasts. Patients were directly enrolled in the CPX-351 Phase I clinical trial and received 134 units / m on a schedule of days 1, 3, and 5 starting January 2, 2008 2 CPX-351. Analysis of bone marrow after 15 days showed hypoplasia (<10% cellularity, <5% b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

Description

[0001] related application [0002] This application claims the benefit of US Application 60 / 901,772, filed February 16, 2007, and US Application 60 / 965,196, filed August 17, 2007, each of which is incorporated herein by reference in its entirety. technical field [0003] The present invention relates to methods for improving the delivery and efficacy of combinations of therapeutic agents. More specifically, the invention relates to the delivery of fixed ratio compositions of cytarabine and an anthracycline (eg, daunorubicin). Background technique [0004] In vitro experiments have shown that anticancer activity can be enhanced when cytotoxic drugs are used in combination. Over the years, this has led to the clinical use of drug combinations such that cytotoxic drug combinations are now the standard for many forms of cancer chemotherapy. New anticancer drugs are typically first recommended to patients as a single drug. After determining the maximum tolerated dose of one ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A01N43/04A61K31/70
Inventor A·路易C·斯温森L·梅尔A·雅诺夫
Owner CELATOR PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com